What is the rationale for referring this patient to a phase II study of cabozantinib or other multi-TKI if she had had surgery and chemotherapy, but shows progression after cytotoxic chemotherapy?

What is the rationale for referring this patient to a phase II study of cabozantinib or other multi-TKI if she had had surgery and chemotherapy, but shows progression after cytotoxic chemotherapy?

What would be the rationale for referring this patient to a phase II study of cabozantinib or other multi-TKI if she had had surgery and chemotherapy, but shows progression to Stage IV disease after two prior lines of cytotoxic chemotherapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Alexander Drilon, MD

Alexander Drilon, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY, USA